Streetbeat News

Price Targets

UNP

BMO Capital has maintained its 'Outperform' rating on Union Pacific (NYSE:UNP) but has slightly lowered the price target from $280 to $275.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:38 pm

SKYE

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:35 pm

FDX

BMO Capital has maintained a Market Perform rating on FedEx and lowered its price target from $325 to $300.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:33 pm

VST

BMO Capital analyst James Thalacker maintains an Outperform rating on Vistra (NYSE:VST) and raises the price target from $120 to $125.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:31 pm

RIGL

Cantor Fitzgerald analyst Kristen Kluska has reiterated a Neutral rating for Rigel Pharmaceuticals (NASDAQ:RIGL) and maintained a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:30 pm

FDS

BMO Capital has maintained a Market Perform rating on FactSet Research Systems and raised its price target from $440 to $471.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:30 pm

CRBP

Corbus Pharmaceuticals Holdings shares are trading lower in sympathy with Novo Nordisk after Novo's Phase2a trial results for Monlunabant in obesity. Wedbush maintained an Outperform rating on Corbus but lowered its price target from $85 to $51.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:29 pm

SLNO

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Soleno Therapeutics (NASDAQ:SLNO) and maintained a price target of $67.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:28 pm

DRI

BMO Capital analyst Andrew Strelzik maintains a Market Perform rating on Darden Restaurants and raises the price target from $165 to $175.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:27 pm

RARE

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and maintained a price target of $116.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:27 pm